Tislelizumab plus sitravatinib as adjuvant therapy for patients with hepatocellular carcinoma at high risk of recurrence after surgical resection: Preliminary analysis of a multi-center, non-randomized, open-label phase 2 study

被引：0
|
作者：
Wang, Jiabei
Peng, Tao
Liu, Chang
Zhang, Ling
Zhu, Guangzhi
Zhang, Xiaogang
Wang, Xiaoqian
Liu, Lianxin
机构：
[1] USTC, Affiliated Hosp 1, Hefei, Peoples R China
[2] Guangxi Med Univ, Affiliated Hosp 1, Nanning, Peoples R China
[3] Xi An Jiao Tong Univ, Affiliated Hosp 1, Xian, Peoples R China
[4] Zhengzhou Univ, Affiliated Canc Hosp, Zhengzhou, Peoples R China
[5] Univ Sci & Technol China, Div Life Sci & Med, Affiliated Hosp 1, Hefei, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16239
引用
收藏
页数：1
相关论文
共 50 条
  • [41] TRIAL IN PROGRESS: AN OPEN-LABEL, MULTI-CENTER PHASE 2 STUDY EVALUATING EFFICACY AND SAFETY OF NARSOPLIMAB FOR THE TREATMENT OF PEDIATRIC HIGH-RISK HSCT-TMA
    Pullman, William
    Brough, Mary
    Soto, Carolina
    Meng, Tze-Chiang
    BONE MARROW TRANSPLANTATION, 2023, 58 (SUPP1) : 523 - 523
  • [42] Safety and efficacy of radiotherapy combined with lenvatinib plus PD-1 inhibitors as neo-adjuvant therapy in hepatocellular carcinoma with portal vein thrombus: protocol of an open-label, single-arm, prospective, multi-center phase I trial
    Li, Guangxin
    Shu, Bin
    Zheng, Zhuozhao
    Yin, Hongfang
    Zhang, Chen
    Xiao, Ying
    Yang, Yanmei
    Yan, Zhe
    Zhang, Xiaofei
    Yang, Shizhong
    Li, Gong
    Dong, Jiahong
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [43] Adjuvant Therapy Combining Donafenib and Sintilimab Enhances Recurrence-Free Survival in Hepatocellular Carcinoma Patients With High-Risk Recurrence Factors After Radical Resection: A Retrospective Cohort Study
    Shen, Hanchuan
    Liu, Bing
    Zhang, Hangyu
    Liu, Yang
    Li, Chenggang
    MEDCOMM-ONCOLOGY, 2025, 4 (01):
  • [44] CABOSUN II: Results from a phase 2, open-label, multi-center randomized study of cabozantinib (CABO) vs. sunitinib (SUN) for non-clear cell renal cell carcinoma (NCCRCC)
    Johns, Andrew
    Campbell, Matthew T.
    Msaouel, Pavlos
    Jonasch, Eric
    Hahn, Andrew Warren
    Gao, Jianjun
    Shah, Amishi Yogesh
    Goswami, Sangeeta
    Zurita, Amado J.
    Pagliaro, Lance C.
    Bilen, Mehmet Asim
    Venkatesan, Aradhana M.
    Rao, Priya
    Tamboli, Pheroze
    Sircar, Kanishka
    Tidwell, Rebecca Slack
    Tannir, Nizar M.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [45] Updated results from ALTER-H004 trial: Anlotinib combined with TACE as adjuvant therapy for patients with hepatocellular carcinoma at high risk of recurrence after surgery-A single arm, multi-center, phase II clinical trial
    Wu, Zheng
    Wang, Zheng
    Zhang, Lei
    Song, Xiaojing
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [46] Trastuzumab, pertuzumab and nab-paclitaxel plus pyrotinib or not in neoadjuvant treatment of HER2-positive breast cancer: A multi-center, randomized, open-label, phase II study.
    Chen, Xiaosong
    Huang, Jiahui
    Tong, Yiwei
    Ren, Weili
    Yu, Jing
    Gao, Weiqi
    Zhu, Siji
    Hong, Jin
    Wu, Jiayi
    Huang, Ou
    He, Jianrong
    Chen, Weiguo
    Li, Yafen
    Shen, Kunwei
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [47] Relatlimab plus nivolumab in patients with advanced hepatocellular carcinoma who are naive to immuno-oncology therapy but progressed on tyrosine kinase inhibitors, a phase 2, randomized, open-label study: RELATIVITY-073
    Sangro, B.
    Numata, K.
    Huang, Y.
    Gomez-Martin, C.
    Hiraoka, A.
    Moriguchi, M.
    Shen, Y.
    Horvath, A.
    Feely, W.
    Young, T.
    Neely, J.
    Kudo, M.
    ANNALS OF ONCOLOGY, 2021, 32 : S117 - S117
  • [48] A multicenter, randomized, controlled, phase II trial exploring adjuvant combined therapy of apatinib and SHR-1210 (anti-PD-1), in patients with hepatocellular carcinoma at high risk of recurrence after radical resection
    Yan, S.
    Zhang, Y.
    Bi, X.
    Zhao, J.
    Du, S.
    Huang, Z.
    Zhang, Y.
    Liu, D.
    Li, Z.
    Zhou, J.
    Cai, J.
    Zhao, H.
    ANNALS OF ONCOLOGY, 2019, 30
  • [49] A phase I, open-label, multi-center, dose-escalation study of codrituzumab, an anti-glypican-3 monoclonal antibody, in combination with atezolizumab in patients with locally advanced or metastatic hepatocellular carcinoma
    Cheng, A-L.
    Yen, C-J.
    Okusaka, T.
    Ikeda, M.
    Hsu, C-H.
    Wu, S-Y.
    Morizane, C.
    Hashimoto, Y.
    Ueshima, K.
    Ohtomo, T.
    Tanaka, T.
    Kudo, M.
    ANNALS OF ONCOLOGY, 2018, 29
  • [50] IMbrave050: Phase 3 study of adjuvant atezolizumab plus bevacizumab versus active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation
    Trojan, J.
    Chow, P.
    Chen, M.
    Cheng, A-L
    Kaseb, A.
    Kudo, M.
    Lee, H. C.
    Yopp, A.
    Zhou, J.
    Wang, L.
    Wen, X.
    Heo, J.
    Tak, W-Y
    Nakamura, S.
    Numata, K.
    Uguen, T.
    Hsieh, D.
    Cha, E.
    Hack, S. P.
    Lian, Q.
    Spahn, J.
    Wu, C.
    Qin, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 239 - 239
12345